Steven Simoens, Jeremy Hurst
OECD Health Working Papers No. 21, OECD, January 2006

There are signs that a higher density of physicians is found in countries which have left the supply of physicians mainly to the market (incl. Slovakia) whereas lower density is found in countries which have planned the intake to medical schools centrally over many years.

Jeremy Hurst, Luigi Siciliani
OECD Health Working Papers No. 6, OECD, July 2003

At worst, waiting times can lead to deterioration in health, loss of utility and extra costs. However, one surprising result is that there is little evidence of health deterioration from a review of studies of patients waiting for a few months for different elective procedures across a range of countries. Moreover, such patients are quite tolerant of short and moderate waits, although the general public often expresses more concern about waiting.

Luigi Siciliani, Jeremy Hurst
OECD Health Working Papers No. 7, OECD, October 2003

There is a clear negative association between waiting times and capacity, either measured in terms of number of beds or number of practising physicians. Analogously, a higher level of health spending is also systematically associated with lower waiting times. Also, evidence from this and other studies suggests that fee-for-service remuneration for specialists, as opposed to salaried remuneration, is negatively associated with the presence of waiting times.

The Office for Fair Trading, 20.2.2007, UK

Úrad pre spravodlivú súťaž vo Veľkej Británii vydal štúdiu, podľa ktorej môže štát usporiť 500 miliónov libier ročne, ak začne regulovať ceny liekov podľa toho, aký úžitok prinesú pre pacienta. V súčasnosti Veľká Británia reguluje ceny podľa ziskovosti výrobcov liekov, prípadne priamymi cenovými zásahmi. Podľa úradu sú niektoré lieky viac ako 10-násobne drahšie než náhradné lieky s podobným účinkom.

Jana Davidová, Lenka Praznovcová, Cecilia Stålsby Lundborg
Pharmacy World & Science No. 1, January, 2008

Porovnanie systémov cenovej regulácie a úhrad za lieky v Českej republike a Švédsku ukázalo, že na rozdiel od ČR, kde ceny liekov môžu byť rozdielne, avšak nie vyššie ako maximálne stanovená cena, sú ceny liekov v celom Švédsku rovnaké, čomu napomáha aj systém štátom vlastnených lekární.